Q-omics provides the consensus-scored SNORA80C profile across patient tissues and cancer cell-line models. SNORA80C expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, SNORA80C is differentially expressed in 6, with the highest sampling consensus in ESCA. Additionally, SNORA80C RNA expression shows 8,381 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight LUSC, ESCA, and DLBC as cancer lineages where SNORA80C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORA80C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORA80C survival associations across molecular data types. SNORA80C RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORA80C RNA expression–survival associations across cancer types. High SNORA80C expression shows unfavorable associations in LUSC, ACC, LGG, KICH and PCPG, but favorable associations in BLCA. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .014). Together, the overview and detailed table identify LUSC as the clearest survival context for SNORA80C RNA expression.
This table summarizes SNORA80C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in ESCA for RNA.
This table ranks reproducible tumor–normal expression differences for SNORA80C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORA80C shows lower tumor expression in THCA and higher tumor expression in ESCA, STAD, LUAD, READ and KIRC. The ESCA box plot shows higher SNORA80C RNA expression in tumor versus normal tissue (log2 FC = +0.636, t-test p = .014).
This table shows molecular features associated with SNORA80C in patient tissues and cancer cell lines. In patient samples, SNORA80C shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
